Bio-Rad Labs (NYSE: BIO) reported Q2 EPS of $3.11, $1.10 better than the analyst estimate of $2.01. Revenue for the quarter came in at $638.5 million versus the consensus estimate of $645.79 million.

GUIDANCE:

Bio-Rad Labs sees Q3 2024 revenue of $638.5-681.1 million, versus the consensus of $661 million.

For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.